

Programm-Überblick

Ort: LMU München, Geschwister-Scholl-Platz 1, 80336 München

8:30-10:30 Symposium XI

A 014 **Tiermodelle in der neuropsychiatrischen Grundlagenforschung**

R Spanagel

8:30-10:30 Symposium XII

A 016 **Neues zur Neurobiologie der Suizidalität**

UW Preuss / D Rujescu

8:30-10:30 Symposium XIII

A 017 **Das Autobiographische Gedächtnis bei leichter kognitiver Beeinträchtigung und Alzheimer-Demenz**

HJ Markowitsch / J Schröder

8:30-10:30 Symposium XIV

A 022 **„Computational Neuropsychiatry“ – towards computer-based theories of disturbed brain functions**

F Tretter / G Winterer

8:30-10:30 Symposium XV

A 119 **Metabolisches Syndrom, Depression, Schlafstörung - neurobiologische Grundlagen und Auswirkungen der Psychopharmakotherapie**

M Deuschle / S Kloiber

10:30-10:45 Pause

10:45-11:45 Hot Topics I

A 014 Polymorphisms in the angiotensin-converting enzyme gene region predict coping styles in healthy adults and depressed patients.
A Heck et al.

CREB-phosphorylation in the course of electroconvulsive therapy (ECT)
M Roesler et al.

Dexamethasone Suppression Test - a tool for decision making in antidepressive treatment?
NC Schommer et al.

Algorithm-guided treatment of depression reduces treatment costs - Results from the German Algorithm Project
R Ricken et al.

10:45-11:45 Hot Topics II

A 016 ¹⁵N metabolic labeling of high and low anxiety-related behavior HAB/LAB mice
MS Keßler et al.

Measuring Orexin in body fluids: A new robust highly sensitive method.
A Jeske et al.

Effects of the NMDA receptor antagonist ketamine on stress hormone system regulation, cognitive functioning and posttraumatic stress symptomatology in accident victims
M Schönenberg et al.

Hyponatremia in elderly psychiatric inpatients – case characteristics in a natural setting
I Blaeser et al.

10:45-11:45 Hot Topics III

A 017 Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome
Ch Richter et al.

Molecular circadian rhythms in humans: effects of age
L Pagani et al.

Sensitivity of dopamine systems to opioidergic stimulation in alcoholism: a PET study with [18F]fallypride
KN Spreckelmeyer et al.

Flavonoid-drug interactions: effects of anthocyanins and anthocyanidins on CYP2D6
A Dreiseitel et al

10:45-11:45 Hot Topics IV

A 022 Multi-Drug-Resistance proteins affect antipsychotic treatment: in vivo effects of aripiprazole.
KM Kirschbaum et al.

Dual-isotope SPECT imaging of striatal dopamine: A comparative study between never treated and haloperidol treated first episode schizophrenic patients
GJE Schmitt et al.

Vicious cycle in Alzheimer's disease: Amyloid beta aggravates its own production
GP Eckert et al.

Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation
S Knolle-Veentjer et al.

11:45-13:45 Poster Lunch II

Angststörungen

Demenz

Sucht

Kinder- und Jugendpsychiatrie

Schlaf

Verschiedenes

13:45-15:45 Symposium XVI

A 014 **Das Restless Legs Syndrom**
R Kohnen / C Trenkwalder

13:45-15:45 Symposium XVII

A 016 **Biomarker für psychiatrische Erkrankungen -
Unterstützung diagnostischer Entscheidungsprozesse
und der Verlaufsbeurteilung in klinischen Prüfungen?**
FM Leweke / J Klosterkötter

13:45-15:45 Symposium XVIII

A 017 **Erweitertes Portfolio für Serotonin ?
Neue Ansätze für 5-HT in Zellbiologie,
Genetik und Neuropsychopharmakologie**
J Priller

13:45-15:45 Symposium XIX

A 022 **Vulnerability and resilience factors in depression and
dementia: From molecular regulation to clinic**
E Holsboer-Trachsler / U Hemmeter

13:45-15:45 Symposium XX

A 119 **Einsatz bildgebender Verfahren zur
Therapieprädiktion und –evaluation der ADHS**
T Frodl / J Krause

15:45-16:00 Pause

16:00-17:45 Satellitensymposium IV

A 140 **Depression und Schlafstörung
Melatonernerger Agonismus - Ein neues Therapiekonzept**
HJ Möller

18:00-18:15 Pause

18:15-19:15 Satellitensymposium V

A 015 **Kognitive Aspekte der Depression und Schizophrenie**

20:00 Festabend im Künstlerhaus

Freitag, 5. Oktober 2007

Programm-Überblick

Ort: LMU München, Geschwister-Scholl-Platz 1, 80336 München

9:00-11:15 Symposium des Vorsitzenden

A 140 J Aldenhoff, Kiel

11:15-11:30 Pause

11:30-13:00 Fortbildungskurs III

A 016 Arzneimittelinteraktionen
Ch Hiemke, G Eckermann, E Jaquenoud Sirot

11:30-13:00 Fortbildungskurs IV

A 017 Probleme und Anforderungen von Investigator initiierten
Studien (IITs) nach der 12. AMG-Novelle
UM Hemmeter

Programm

Ort: LMU München, Geschwister-Scholl-Platz 1
80336 München

8:30-10:30 Symposium XI

Tiermodelle in der neuropsychiatrischen Grundlagenforschung
Vorsitz: Rainer Spanagel

I Sillaber, München,
Depression

M Koch, Bremen,
Schizophrenie

M Schneider, Mannheim,
Sucht

F Crestani, Zürich,
Angst

8:30-10:30 Symposium XII

Neues zur Neurobiologie der Suizidalität

Vorsitz: Ulrich W. Preuss / Dan Rujescu

D Rujescu, München
Genetik aggressiven und impulsiven Verhaltens

UW Preuss, Halle
Interaktion von genetischen und psychosozialen Faktoren bei suizidalem Verhalten

M Johann, Regensburg
Dopaminerges System und Suizidalität unter Berücksichtigung von Alkoholabhängigkeit und ADHS

Th Bronisch, München
Pharmakotherapeutische und neurobiologische Grundlagen suizidalen Verhaltens

8:30-10:30 Symposium XIII

**Das autobiographische Gedächtnis bei leichter kognitiver
Beeinträchtigung und Alzheimer-Demenz**

Vorsitz: H.J. Markowitsch / J. Schröder

J Schröder, Heidelberg
Was ist autobiographisches Gedächtnis?

U Seidl, Heidelberg
Störungen des autobiographischen Gedächtnis bei Alzheimer Demenz

E Ahlsdorf, Heidelberg
Differenzialdiagnostische Untersuchungen zum autobiographischen
Gedächtnis

S Matura, Frankfurt
Eine fMRI Studie zum autobiographischen Erinnern von Patienten mit
leichter kognitiver Beeinträchtigung

8:30-10:30 Symposium XIV

**„Computational Neuropsychiatry“ – towards computer-based theories
of disturbed brain functions**

Vorsitz: Felix Tretter / Georg Winterer

G Deco, Barcelona

Zur Bedeutung der „computational neuroscience“ für die Psychiatrie–
Konzepte, Methoden, Modelle

G Winterer, Düsseldorf

Schizophrenie als Störung der Signal/Noise Ratio

J Gallinat, Berlin

Kombinierte Transmitter-Messungen

R Schlösser, Jena

Mathematische Basis der fMRI-Methodik

8:30-10:30 Symposium XV

Metabolisches Syndrom, Depression, Schlafstörung neurobiologische Grundlagen und Auswirkungen der Psychopharmakotherapie

Vorsitz: Michael Deuschle / Stefan Kloiber

M Deuschle, Mannheim
HPA-Aktivierung bei Depression und Metabolisches Syndrom

S Kloiber, München
Genetische Risikofaktoren für Metabolische Erkrankungen bei unipolarer Depression

H Himmerich, Marburg
Das Zusammenspiel metabolischer und immunologischer Veränderungen bei psychiatrischen Erkrankungen und unter psychopharmakologischer Therapie

A Schuld, Ingolstadt
Metabolische Veränderungen bei Patienten mit chronischen psychiatrischen Erkrankungen unter neuroleptischer Langzeittherapie

P Beitinger, München
Metabolisches Syndrom bei Narkolepsie

10:45-11:45 Hot Topics I

Vorsitz: Werner Kadus

Polymorphisms in the angiotensin-converting enzyme gene region predict coping styles in healthy adults and depressed patients.

Heck A, Lieb R, Ellgas A, Pfister H, Lucae S, Erhardt A, Himmerich H, Horstmann S, Kloiber S, Ripke S, Müller-Myhsok B, Bettecken T, Uhr M, Holsboer F, Ising M

Munich

CREB-phosphorylation in the course of electroconvulsive therapy (ECT)

Roesler M, Trott G-E, Philipsen A, Gerwe M, Lee E, Medori R, Schauble B
Kiel

Dexamethasone Suppression Test - a tool for decision making in antidepressive treatment?

Schommer N C, Schulz-Ratei B, Schlattmann P, Anghelscu I, Heuser I
Berlin

Algorithm-guided treatment of depression reduces treatment costs - Results from the German Algorithm Project

Ricken R¹, Schietsch K¹, Reinhold T¹, Bauer M², Adli M¹

¹ Berlin, ² Dresden

10:45-11:45 Hot Topics II

Vorsitz: W.Wolfgang Fleischhacker

15N metabolic labeling of high and low anxiety-related behavior

HAB/LAB mice

Keßler MS, Frank E, Filiou MD, Zhang YY, Haegler K, Maccarrone G,
Hambach B, Landgraf R, Turck CW

Munich

Measuring Orexin in body fluids: A new robust highly sensitive method.

Jeske A, Hinze-Selch D

Klinik für Psychiatrie und Psychotherapie am Zentrum für Integrative
Kiel

Effects of the NMDA receptor antagonist ketamine on stress hormone
system regulation, cognitive functioning and posttraumatic stress
symptomatology in accident victims

Schönenberg M¹, Wilk K¹, Jacob H¹, Reichwald U¹, Domes G²,
Hautzinger M¹

¹ Tübingen² Rostock

Hyponatremia in elderly psychiatric inpatients – case characteristics in a
natural setting

Blaeser I, Gillmann A, Supprian T, Lange-Asschenfeldt C
Düsseldorf

10:45-11:45 Hot Topics III**Vorsitz: Barbara Sperner-Unterweger**

Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome

Richter Ch.¹, Schmitt C¹, Kienast Th.¹, Hinzpeter A.¹, Schäfer M.²
¹ Berlin, ²Essen

Molecular circadian rhythms in humans: effects of age

Pagani L¹, Waldmeier L¹, Meier F¹, Izakovic J¹, Cajochen C¹, Wirz-Justice A¹, Brown SA², Eckert A¹
¹ Basel, Switzerland, ² Zürich, Switzerland

Sensitivity of dopamine systems to opioidergic stimulation in alcoholism: a PET study with [18F]fallypride

Spreckelmeyer KN, Paulzen M, Fellows C, Ntoubas A, Vernaleken I, Schäfer W, Gründer G
Aachen

Flavonoid-drug interactions: effects of anthocyanins and anthocyanidins on CYP2D6

Dreiseitel A¹, Schreier P², Hajak G¹, Sand PG²
¹ Regensburg ² Wuerzburg

10:45-11:45 Hot Topics IV

Vorsitz: Axel Steiger

Multi-Drug-Resistance proteins affect antipsychotic treatment: in vivo effects of aripiprazole

Kirschbaum KM¹, Uhr M², Hiemke C¹, Schmitt U¹

¹ Mainz² Munich

Dual-isotope SPECT imaging of striatal dopamine: A comparative study between never treated and haloperidol treated first episode schizophrenic patients

Schmitt GJE, Dresel S, Frodl T, La Fougère C, Hahn K, Möller H-J,

Meisenzahl EM

Munich

Vicious cycle in Alzheimer's disease: Amyloid beta aggravates its own production

Eckert GP¹, Peters I¹, Wood WG², Müller WE¹

¹ Frankfurt, ² Minnesota

Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation

Knolle-Veentjer S, Huth V, Ferstl R, Aldenhoff J, Hinze-Selch D

Kiel

11:45-13:45 Poster Lunch II**Anxiety Disorders**

- 1 Hyponatremia in elderly psychiatric inpatients – case characteristics in a natural setting
Blaeser I, Gillmann A, Supprian T, Lange-Asschenfeldt C
Düsseldorf
- 2 Expressing emotions: Avp and Crh are involved in the phenotype of mice bred for extremes in anxiety-related behavior
Bunck M¹, Czibere L¹, Schmidt MV¹, Rafael J¹, Muigg P², Panhuysen M¹, Pütz B¹, Deussing JW¹, Singewald N², Holsboer F¹, Wigger A¹, Landgraf R¹
¹ Munich, ² Innsbruck, Austria
- 3 Control of the anterior cingulate/mPFC over the amygdala: a longitudinal fMRI study in patients with panic disorder
Chechko N, Czisch M, Erhardt A, Hoehn D, Wehrle R, Sämann P
Munich
- 4 The role of tachykinin 1 in a mouse model of trait anxiety
Czibere L, Baur-Jaronowski LA, Weber P, Pütz B, Panhuysen M, Deussing JM, Landgraf R
Munich
- 5 A genome-wide association study in patients with panic and anxiety disorders
Erhardt A,¹ Unschuld PG,¹ Ripke S,¹ Lucae S,¹ Kohli M,¹ Kloiber S,¹ Puetz B,¹ Heck A,¹ Ellgas A,¹ Pfister H,¹ Ising M,¹ Bettecken T,¹ Müller-Myhsok B,¹ Keck ME,² Holsboer F,¹
¹ Munich, ² Oetwill am See
- 6 Functional neuroanatomy of CCK-4 induced panic attacks in healthy volunteers
Eser D, Leicht G, Lutz J, Kirsch V, Schüle C, Karch S, Baghai T, Pogarell O, Born C, Rupprecht R, Mulert C
Munich
- 7 Role of contextual fear memory in development of Posttraumatic Stress Disorder (PTSD)-like symptoms in mice
Golub Y, Wotjak CT
Munich

-
- 8 Serotonergic and dopaminergic stimulation in relation to approach-avoidance behavior in patients with Anxiety disorders and Borderline Personality disorder
Hemmeter U¹, Kundermann B¹, Nekwasil B¹, Thum A¹, Schneyer T¹, Bender M², Huber M¹, Giesler M¹, Krieg JC¹
¹ Marburg, ² Herborn
- 9 ¹⁵N metabolic labeling of high and low anxiety-related behavior
HAB/LAB mice
Keßler MS, Frank E, Filiou MD, Zhang YY, Haegler K, Maccarrone G, Hamsch B, Landgraf R, Turck CW
Munich
- 10 Disturbed function of the growth hormone axis and the HPA axis in obsessive compulsive disorder
Michael Kluge, Petra Schüssler, Martin Dresler, Alexander Yassouridis, Axel Steiger
Munich
- 11 Specific vulnerability and risk factors for the onset of panic disorder, agoraphobia and other phobias
Nocon, A., Brückl, T., Zimmermann, P., Lieb, R., Wittchen, H.-U¹
¹ Munich, ² Dresden, ³ Basel
- 12 Long-term efficacy of cognitive-behavioral therapy of patients with anxiety disorders in a hospital setting – influence of continuing psychotherapy and pharmacotherapy
Rathgeb-Fuetsch M, Beer U, Urmann I, Pollmächer T, Schuld A
Ingolstadt
- 13 The effect of acute immobilization stress on the expression of synaptic proteins in serotonin transporter deficient mice
Sarah Louise Nietzer, Angelika G. Schmitt, Gabriela Ortega, Claudia Kriegebaum, Lise Gutknecht, Klaus-Peter Lesch
Würzburg, Germany
- 14 Effects of the NMDA receptor antagonist ketamine on stress hormone system regulation, cognitive functioning and posttraumatic stress symptomatology in accident victims
Schönenberg M¹, Wilk K¹, Jacob H¹, Reichwald U¹, Domes G², Hautzinger M¹
¹ Tübingen, ² Rostock
- 15 Characterization of dopamine release and metabolism in the prefrontal cortex of C57BL/6L and BALB/c mice
Thoeringer CK¹, Bächli H², Flachskamm C¹, Wotjak CT¹
¹ Munich, ² Basel

- 16 Rapid tryptophan depletion affects behavioural inhibition and cognitive flexibility in hostile children with ADHD
Zepf, FD, Holtmann, M, Stadler, C, Schmitt, M, Poustka, F
Frankfurt am Main

11:45-13:45 Poster Lunch II**Dementia**

- 17 Vicious cycle in Alzheimer's disease: Amyloid beta aggravates its own production
Eckert GP¹, Peters I¹, Wood WG², Müller WE¹
¹ Frankfurt, ² Minnesota
- 18 A-beta peptide signatures in brains, CSF and blood plasma from APP23 transgenic mice
Hans-W. Klafki¹, Sabine Paul¹, Hermann Esselmann¹, Sabine Leuthäusser², Matthias Staufenbiel², Jens Wiltfang¹
¹ Erlangen-Nuremberg, ² Basel, Switzerland
- 19 Decreases of hematopoietic stem cells in early Alzheimer's disease
Juan Manuel Maler, Philipp Spitzer, Piotr Lewczuk, Johannes Kornhuber, Martin Herrmann, Jens Wiltfang
Erlangen
- 20 Determination of rivastigmine in serum using solid phase extraction and high performance liquid chromatography coupled to UV detection technique for routine medical analysis.
Koeber R, Bader W, Jahner T, Melchner D, Haen E
Regensburg
- 21 Mitochondrial failure in a transgenic mice model of Alzheimer's disease with plaques and tangles
Rhein V¹, Baysang G¹, Meier F¹, Ozmen L², Bluethmann H², Savaskan E¹, Müller-Spahn F¹, Czech C², Götz J³, Eckert A¹
¹ Basel, Switzerland, ² Basel, Switzerland, ³ Sydney, Australia
- 22 Chronic inhibition of brain phospholipase A2 in rats as a model to investigate Alzheimer-related alterations: a preliminary study
Schaeffer EL¹, Schmitt A², Gattaz WF¹
¹ Sao Paulo, Brazil, ² Göttingen
- 23 CSF tau protein in the early diagnosis of Alzheimer's disease – a follow-up study
Peter Schönknecht¹, Elmar Kaiser², Pablo Toro², Johannes Schröder²
¹ Leipzig, ² Heidelberg

11:45-13:45 Poster Lunch II**Addiction**

- 24 Reliability and Validity of the German Version of the 49-item -
Addiction Research Center Inventory in a sample of detoxified
alcoholic patients
Bopp, G.¹, Benda, J.², Glasmacher, C.³, Schütz, C.G.⁴
¹⁻³ Bonn, ² Munich
- 25 Rivastigmine reduces smoking - an observational case series.
Diehl A, Paslakis G, Mutschler J, Rockenbach C, Nakovics H, Mann K
Mannheim
- 26 Prediction of outcome by multimodal monitoring of treatment
processes in alcoholism therapy
Henning Krampe, Sabina Stawicki, Silja Niehaus, Katja Ribbe, Thilo
Wagner, Claudia Bartels, Birgit Kröner-Herwig, Hannelore Ehrenreich
Göttingen
- 27 High level of harm avoidance is associated with SLC6A4 functional
haplotypes in alcohol dependent subjects
Koller¹, Preuss², Zill¹, Skoruppa¹, Bondy¹, Soyka¹
¹ München, ² Halle
- 28 Brain imaging of alcohol craving and the role of acamprosat: a fMRI-
study
Langosch, JM, Feige, B, Jahnke, K, Spiegelhalder, K, Kiemen, A, Paul,
D, Speck, O, Hennig, J, Berger, M, Olbrich, HM
Freiburg
- 29 Levetiracetam and Disulfiram for relapse prevention in patients with
alcohol dependence
Lorenz Hilwerling, Katharina Assmann, Kathrin Griese, Alfred Wähner
Bochum
- 30 Elevated alcohol consumption in mice lacking functional natriuretic
peptide-A receptor
Mutschler J¹, Bilbao A², Goltz Ch¹, Jahn H³, Spanagel R², Wiedeman
K³, Kiefer F¹
^{1,2} Heidelberg, ³ Hamburg

- 31 Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome
Richter, Ch.¹, Schmitt, C¹, Kienast, Th.¹, Hinzpeter, A.², Schäfer, M.³
^{1,2}Berlin, ³ Essen
- 32 Sensitivity of dopamine systems to opioidergic stimulation in alcoholism: a PET study with [18F]fallypride
Spreckelmeyer KN, Paulzen M, Fellows C, Ntoubas A, Vernaleken I, Schäfer W, Gründer G
Aachen
- 33 Association between plasma atrial natriuretic peptide, β -endorphin and anxiety in mice during acute ethanol withdrawal
von der Goltz C, Mutschler J, Kiefer F
Mannheim
- 34 Atomoxetine treatment of adults with ADHD and comorbid alcohol abuse disorder
Wilens TE¹, Adler LA², Weiss MD³, Ramsey JL⁴, Moore RJ⁴, Renard D⁵, Trzepacz PT⁴, Schuh LM⁴, Dittmann RW⁶, Levine LR⁴
¹Boston, MA, USA, ²New York, NY, USA, ³Vancouver, BC, CAN, ⁴Indianapolis, IN, USA, ⁵Brussels, Belgium, ⁶ Hamburg, ⁷ Bad Homburg
- 35 Effect of alcohol on hypothalamus neurons
Wollweber BT¹, Braun HA², Voigt K²
¹Munich, ² Marburg

11:45-13:45 Poster Lunch II**Child- and Adolescent Psychiatry**

- 36 Methylphenidate effects on cell growth and maturation in neuronal stem cells
Bartl J², Gruenblatt E², Gerlach M³, Riederer P³, Mori T¹, Ozawa H¹
¹Nagasaki, Japan, ^{2, 3} Würzburg
- 37 Effects of methylphenidate on neuropsychological functioning of boys with ADHD
Hellwig-Brida S, Goldbeck L
Ulm
- 38 Quality of life of children with ADHD - prospective, multicenter non-interventional leco-trial evaluating the impact on QOL, effectiveness and tolerability of OROS®-methylphenidate
Klose N¹, Gerwe M¹, Hargarter L¹, Czekalla J¹, Mattejat F²
¹Neuss, ² Gießen und Marburg
- 39 GIRK2 - A novel candidate gene for attention deficit hyperactivity disorder
Röser C¹, Renner TJ², Walitza S², Dempfle A³, Nguyen T³, Romanos M², Jacob C¹, Reif A¹, Schäfer H³, Gerlach M², Warnke A², Lesch KP¹
^{1,2} Wuerzburg, ³ Marburg
- 40 Treatment with extended-release methylphenidate (OROS®-MPH) in children with ADHD is associated with improvement in social functioning throughout the active day – results from an open-label, non-interventional trial
Stollhoff K¹, Schauble B², Czekalla J², Klose N², Gerwe M²
¹Hamburg-Altona, ²Neuss
- 41 Reduced intracellular platelet Ca²⁺ responses to serotonin in patients with anorexia and bulimia nervosa increase under antidepressant medication
Wöckel L¹, Koch S³, Meyer-Keitel A-E², Zepf F¹, Schmidt MH², Poustka F¹
¹ Frankfurt / Main, ²Mannheim, ³ Heidelberg

11:45-13:45 Poster Lunch II**Sleep**

- 42 Metabolic and cardiovascular risk factors in narcolepsy
Beitinger PA, Wehrle R, Fulda S, Himmerich H, Pollmächer T, Wetter
TC
Munich
- 43 Synergistic effects of age and depression on sleep-dependent
memory consolidation
Dresler M, Kluge M, Genzel L, Schüssler P, Steiger A
Munich
- 44 Analysis of sleep-EEG from depressed patients
Figuroa C¹, Schwarz U¹, Kurths J¹, Postnova S², Braun H², Hemmeter
U³
¹ Potsdam, ² Marburg, ³ Marburg, ⁴
- 45 Increased prevalence of restless legs syndrome in narcoleptic
patients
Fulda S, Beitinger PA, Wehrle R, Himmerich H, Pollmächer T, Wetter
TC
Munich
- 46 Cognitive functions in patients with restless legs syndrome
Fulda S, Winkelmann J, Wetter TC
Munich
- 47 Slow wave sleep and REM sleep awakenings do not affect sleep
dependent memory consolidation
Genzel L, Dresler M, Wehrle R, Kluge M, Schüssler P, Steiger A
Munich
- 48 Prevalence of restless leg syndrome in psychiatric population
Lattova Z¹, Maurovich-Horvat E¹, Nia S², Pollmächer T²
¹München, ² Ingolstadt

- 49 Sleep spindles in Kindergarten children: Relation to sleep, hypothalamic-pituitary-adrenocortical (HPA) activity and emotional behavioural abnormalities
Mikoteit T¹, Brand S², Perren S³, von Wyl A⁴, von Klitzing K⁵, Holsboer-Trachsler E², Hatzinger M¹
^{1,2,6,7} Basel, ³ Zurich, ⁵ Leipzig
- 50 Pituitary adenylate cyclase activating peptide (PACAP) affects homeostatic sleep regulation in healthy young men
Murck H, Antonijevic I A, Frieboes RM, Steiger A
Munich
- 51 Molecular circadian rhythms in humans: effects of age
Pagani L¹, Waldmeier L¹, Meier F¹, Izakovic J², Cajochen C³, Wirz-Justice A³, Brown SA⁴, Eckert A¹
¹⁻³Basel, ⁴ Zürich
- 52 Effects of age and gender on sleep-related plasma renin levels
Schüssler P, Kluge M, Uhr M, Dresler M, Frick H, Zuber V, Holsboer F, Yassouridis A, Steiger A
Munich
- 53 The effects of partial sleep deprivation on response inhibition studied by combined functional MRI and EEG
Schmidt C¹, Wehrle R¹, Stiegler A¹, Peters H¹, Wetter T¹, Rieger M², Sämann P¹, Czisch M¹
¹Munich, ² Leipzig
- 54 Increase of respiratory events after treatment with sodiumoxybat in a patient with narcolepsy and mild obstructive sleep apnoea syndrome (SAS): A case report
Seeck-Hirschner M, von Freier A, Aldenhoff J, Göder R
Kiel
- 55 Daytime sleep after glucose intake in patients with narcolepsy
Wehrle R, Beitinger P, Dalal M, Schuld A, Wetter TC, Pollmächer T
Munich

11:45-13:45 Poster Lunch II**Miscellaneous**

- 56 Generation of a CRH-Cre mouse line to analyze the CRH system
Ableitner M., Holsboer F., Wurst W., Kühn R., Deussing J.M.
Munich
- 57 Long-term, open-label safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: final report of a 4-year study
Adler L¹, Spencer TJ², Williams DW³, Moore R³, Dittmann RW⁴, Michelson D³
¹New York, NY, USA, ²Boston, MA, USA, ³Indianapolis, IN, USA, ⁴Hamburg, ⁵Bad Homburg
- 58 Deep brain stimulation of the globus pallidus differentially affects compulsive checking behavior in rats
Anais Djodari-Irani, Julius Klein, Andreas Heinz, Rudolf Morgenstern, Christine Winter
Berlin
- 59 Treatment of Tourette's syndrome with aripiprazole
Bartels M
Tuebingen
- 60 Serotonin serves as maintenance factor in adult neural stem cells mainly via the 5-HT1A receptor subtype
Benninghoff J¹, Gritti A², Rizzi M², Schmitt A³, Genius J¹, Rujescu D¹, Lesch KP³, Möller H-J¹, Vescovi AL²
¹ Munich, ² Milano, ³ Würzburg
- 61 Modulation of subthalamic nucleus activity differentially affects compulsive behavior in rats.
Christine Winter¹, Daphna Joel², Oded Klavir², Adrian Mundt¹, Rafed Jalali³, Shira Flash², Julia Klein¹, Daniel Harnack³, Rudolf Morgenstern⁴, Georg Juckel⁵, Andreas Kupsch³
^{1,3,4} Berlin, ²Tel Aviv, ⁵ Bochum
- 62 Flavonoid-drug interactions: effects of anthocyanins and anthocyanidins on CYP2D6
Dreiseitel A¹, Schreier P², Hajak G¹, Sand PG⁶
¹ Regensburg, ² Wuerzburg

- 63 The role of medication in suicide attempts in Switzerland
Flavio Muheim, Martin Eichhorn, Pascal Berger, Stephanie Czernin, Anita Riecher-Rössler, Gabriela Stoppe
Basel
- 64 Low resolution electromagnetic tomography (LORETA) and SSRI response in obsessive-compulsive disorder
Folkerts M¹, Mulert C¹, Karch S¹, Leicht G¹, Mergl R², Schaaff N¹, Zaudig M³, Juckel G⁴, Riedel M¹, Hegerl U², Pogarell O¹
¹ Munich, ² Leipzig, ³ Windach, ⁴ Bochum
- 65 Melatonin suppression by blue narrow-band light emitting diodes in healthy subjects - comparison with bright white light
Franke, Leonora, Sülflow, David, Stark, Katharina, Uebelhack, Ralf
Berlin
- 66 Pharmacological validation of a novel home cage activity counter in mice
Ganea K, Liebl C, Sterlemann V, Müller MB, Schmidt MV
Munich
- 67 Dissecting CRHR1-mediated pathways via microarray technology
Graf C, Weber P, Pütz B, Holsboer F, Wurst W, Deussing JM
Munich
- 68 Cortisol response during pair associate learning under stressful conditions in volunteers: Relationship to learning and memory performance
Haag A, Gieser M, Thum A, Flux B, Klee P, Kundermann B, Krieg JC, Hemmeter U
Marburg
- 69 Therapeutic Drug Monitoring in Psychiatry – Genotyping amends clinical pharmacological comments
Hader A¹, Kirchheiner J², Jahner T¹, Haen E¹
¹ Regensburg, ² Ulm
- 70 Corticotropin Releasing Hormone (CRH) targets various neuroprotective mechanisms
Hanstein R, Behl C, Clement A
Mainz
- 71 Longitudinal association between health-related quality of life and personality factors in patients with amyotrophic lateral sclerosis (ALS)
Henning Krampe¹, Claudia Bartels¹, David Victorson², Craig K. Enders³, Jennifer Beaumont², David Cella², Hannelore Ehrenreich¹
¹Göttingen, ²Evanston, Illinois, USA, ³Tempe, Arizona, USA

- 72 Measuring Orexin in body fluids: A new robust highly sensitive method.
Jeske A, Hinze-Selch D
Kiel
- 73 Magnetic resonance imaging and event related potentials of performance monitoring in patients with attention deficit hyperactivity disorder
Karch S, Thalmeier T, Lutz J, Cerovecki A, Hock B, Leicht G, Born C, Mulert C, Riedel M, Pogarell O
Munich
- 74 The hsp70 cochaperones BAG-1M and HspBP1 as possible cause for glucocorticoid resistance
Knapp RT, Holsboer F, Rein T
Munich
- 75 Protein expression profiling of human glatiramer acetate (GA) and myelin basic protein (MBP) specific T cell lines from a multiple sclerosis (MS) patient and healthy donors
Knop M, Jastorff A, Vargas V, Hornung J, Turck C, Weber F
Munich
- 76 Effects of mineralo-corticoid receptor modulation by spironolactone and fluorocortisone on cortisol secretion and learning performance under a stressful learning task
Kundermann B, Hemmeter U, Giesler M, Thum A, Flux B, Klee P, Haag A, Krieg JC
Marburg
- 77 Analysis of gene expression and regulation of a novel, stress-inducible transcript in the mouse
Liebl C, Schülke J¹, Schmidt MV¹, Trümbach D², Rein T¹, Müller MB¹
¹ Munich, ² Neuherberg
- 78 Dopaminergic modulation of manipulation processes in human working memory – critical involvement of D2 receptors and the ventral striatum
Müller U¹, Dodds C³, Dove A⁴, van Loun A¹, Owen A⁴, Regenthal R⁵, Sahakian BJ², Bullmore ET², Clark L³, Robbins TW¹
¹⁻⁴ Cambridge, GB, ⁵ Leipzig

- 79 Global DNA Methylation is influenced by smoking behavior
Marc.A.N.Muschler¹,Thomas Hillemacher¹,Helge Frieling¹,Susanna Moskau²,A. Semmler²,Johannes Kornhuber¹,Thomas Klockgether²,Michael Linnebank²,Stefan Bleich¹
¹ Erlangen,²Bonn
- 80 Time course of perception in facial expression of emotion in Borderline Personality Disorder (BPD): a Magnetoencephalographic (MEG) study
Merkl, Angela¹,Sander, Tilmann²,Aust, Sabine³,Röpke, Stefan¹,Reinecker, Hans³,Trahms, Lutz²,Heuser, Isabella¹
¹Berlin,²Berlin,³Bamberg
- 81 Deep brain stimulation of the nucleus accumbens core and shell differentially reduce quinpirole induced compulsive checking behavior in rats
Mundt A¹,Klein J¹,Heinz A¹,Morgenstern R¹,Juckel G²,Kupsch A¹,Winter C¹
¹ Berlin, ²Bochum,
- 82 Branched chain amino acids decrease top-down event-related potentials in healthy subjects
Neuhaus AH¹,Goldberg TE²,Hassoun Y²,Bates JA²,Nassauer KW²,Sevy S²,Opgen-Rhein C¹,Malhotra AK²
¹Berlin,²New York City, NY, USA
- 83 Problems related to psychopharmacological treatment: A risk factor of inpatient suicidal behaviour?
Neuner T, Schmid R, Spiessl H
Regensburg
- 84 Functional Consequences of the accumulation of psychopharmacological drugs in "lipid rafts" on ligand-gated ion channels
Nothdurfter C, Eisensamer B, Rein T, Rammes G, Uhr M, Henes K, Wagner E-M, Zieglgänsberger W, Holsboer F , Rupprecht R
Munich
- 85 EEG-vigilance and BOLD-response
Olbrich S¹,Mulert C²,Karch S²,Leicht G²,Hegerl U¹
¹ Leipzig, ² München
- 86 EEG-vigilance retest reliability
Olbrich S, Sander C, Schönknecht P, Bader C, Hegerl U
Leipzig

- 87 Open-label (OL) extension trial of the safety and tolerability of OROS® methylphenidate in adults with ADHD
Philipsen A¹, Trott G-E², Roesler M³, Gerwe M⁴, Lee E⁵, Medori R⁶, Schauble B⁴
¹ Freiburg, ² Aschaffenburg, ³ Homburg/Saar, ^{4,6} Neuss, ⁵ Beerse, Belgium
- 88 Efficacy and safety of OROS® methylphenidate in adults with ADHD: the long-acting methylphenidate in adult ADHD (LAMDA) trial
Roesler M¹, Trott G-E², Philipsen A³, Gerwe M⁴, Lee E⁵, Medori R⁶, Schauble B⁴
¹ Homburg/Saar, ² Aschaffenburg, ³ Freiburg, ^{4,6} Neuss, ⁵ Beerse, Belgium
- 89 Melatonin and serotonin related characteristics in morning-type and evening-type individuals
Sülflow D, Franke L, Stark K, Piazena H, Uebelhack R
Berlin
- 90 The GQS - a measure for the health related self-concept
Sander C¹, Schröder H²
Leipzig
- 91 The effect of acute immobilization stress on the expression of synaptic proteins in serotonin transporter deficient mice
Sarah Louise Nietzer, Angelika G. Schmitt, Gabriela Ortega, Claudia Kriegebaum, Lise Gutknecht, Klaus-Peter Lesch
Würzburg
- 92 [123I] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects
Schaaff N¹, Koch W², Pöpperl G², Tatsch K², Reicherzer M³, Ehmer-von Geiso C⁴, Mulert C¹, Möller H-J¹, Hegerl U⁵, Pogarell O¹
¹⁻⁴ Munich, ³ Tegernsee, ⁵ Leipzig
- 93 The Loudness Dependence of Auditory Evoked Potentials in patients with borderline personality disorder and healthy control subjects
Schaaff N¹, Mulert C¹, Leicht G¹, Karch S¹, Reicherzer M², Ehmer-von Geiso C³, Koch W⁴, Folkerts M¹, Juckel G⁵, Möller H-J¹, Hegerl U⁶, Pogarell O¹
^{1,3,4} Munich, ² Tegernsee, ⁵ Bochum, ⁶ Leipzig

- 94 The functional connectivity of the posterior orbitofrontal cortex - A network for adaptive processing of motivational relevance
Schlueter EK, Gruber O
Goettingen, Germany
- 95 Side effects and non-compliance as causes of inpatient suicides – different assessments of caregivers and professionals
Schmid R, Mehlsteibl D, Schielein T, Hübner-Liebermann B, Spiessl H
Regensburg, Germany
- 96 The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder
Schmitt A G¹, Hall F S², Kreutzfeldt M¹, Perona M T G², Ortega M¹, Hofmann M¹, Siemer M¹, Nietzer S L¹, Sora I³, Uhl G R², Riederer P¹, Gerlach M⁴, Lesch K-P¹, Grünblatt E¹
¹ Würzburg, ²NIH/DHHS, USA, ³ Tohoku, JAPAN, ⁴ Würzburg
- 97 Acromegalic patients: more depressed, without panic? The 'endocrine psychosyndrome' of acromegaly revised
Sievers, C.¹, Dimopoulou, C.¹, Pfister, H.¹, Lieb, R.¹, Steffin, B.², Roemmler, J.², Schopohl, J.², Schneider, H.J.¹, Ising, M.¹, Wittchen, H.-U.³, Saemann, P.G.¹, Czisch, M.¹, Wendl, A.¹, Zihl, J.¹, Stalla, G.K.¹
¹ Munich, ² Munich, ³ Dresden
- 98 Computational Systems Neuropsychiatry - perspectives of a theoretical neuropsychiatry
Tretter F
München
- 99 Prediction of functional inhibition of acid sphingomyelinase and acid ceramidase
Tripal P¹, Reichel M¹, Gulbins E², Kornhuber J¹
¹ Erlangen, ² Duisburg-Essen
- 100 Conditional overexpression of corticotropin-releasing hormone - an animal model for understanding the development of corticotropin-releasing hormone-mediated brain pathology
Walser SM, Vogl AM, Refojo D, Lu A, Steiner MA, Holsboer F, Wotjak CT, Wurst W, Deussing JM
Munich

- 101 Using viral vectors to study local gene function in the mouse brain
Weber P¹, Kamprath K¹, Micale V¹, Kügler S², Wotjak CT, Deussing JM
¹ Munich, ² Göttingen
- 102 Epigenetic regulation of the human EAAT2 gene expression in glioma cells and normal brain
Zschocke J¹, Allritz C², Engele J², Rein T¹
¹ Munich, ² Leipzig
- 103 Die Entwicklung der AGNP im Spiegel ihrer Archivalien
W Burgmair und MM Weber
München
- 104 Effectiveness and tolerability of the long-acting OROS[®] methylphenidate (OROS-MPH) in patients previously treated with Atomoxetine (ATX) or another extended-release methylphenidate (ER-MPH; Medikinet retard[®]) - GER-CON-2
Wolff C¹, Gerwe M², Hargarter L², Bogdanow M³, Schauble B²
¹ Hagen, ² Neuss, ³ Leverkusen
- 105 EEG wavelet analysis: comparison of errors and correct responses
Leopold Zizlsperger¹, Susanne Karch¹, Gregor Leicht¹, Ulrich Hegerl^{1,2}, Hans-Jürgen Möller¹, Oliver Pogarell¹, Christoph Mulert¹
¹ Munich, ² Leipzig
- 106 Evoked potentials in a patient with Charles Bonnet Syndrome
Dagmar A. Schmid^{1,2}, Valentine Marcar³, Lutz Jäncke³, Magdalena Berkhoff,²
¹ Oetwil am See, Switzerland, ^{2,3} Zürich, Switzerland

13:45-15:45 Symposium XVI

Das Restless Legs Syndrom

Vorsitz: Ralf Kohnen / Claudia Trenkwalder

H Beneš, Schwerin/ Rostock

Einführung: Definition, Diagnose, Differentialdiagnose des RLS und epidemiologische Daten

C Trenkwalder, Kassel

Pathophysiologie des RLS

J Winkelmann, München

Neues zur Genetik des RLS

R Kohnen, Nürnberg

Methoden der RLS-Forschung und klinische Studien

K Stiasny-Kolsterl, Marburg

Pharmakotherapie des RLS

B Högl, Innsbruck

Therapiekomplicationen beim RLS

M Hornyak, Freiburg

RLS und psychiatrische Komorbidität

13:45-15:45 Symposium XVII

Biomarker für psychiatrische Erkrankungen – Unterstützung diagnostischer Entscheidungsprozesse und der Verlaufsbeurteilung in klinischen Prüfungen?

Vorsitz: F. Markus Leweke / Joachim Klosterkötter

J Wiltfang, Erlangen

Fortschritte in der neurochemischen Früh- und Differenzialdiagnostik
demenzieller Erkrankungen

H Jahn, Hamburg

Biomarker synaptischer Funktion bei dementiellen Erkrankungen: Die
Hoffnung auf bessere Früh- und Differenzialdiagnostik

S Bahn, Cambridge

Biomarkerprofile für schizophrene und bipolare Erkrankungen

FM Leweke, Köln

Biomarkerprofile in Prodromalstadien von Psychosen - Zusammenhänge mit
der Symptomatik?

13:45-15:45 Symposium XVIII

Erweitertes Portfolio für Serotonin ?

Neue Ansätze für 5-HT in Zellbiologie, Genetik und Neuropsychopharmakologie

Vorsitz: Josef Priller

D Walther, Berlin

„Serotonylation“, ein neuer Mechanismus der intrazellulären, serotonergen Informationsübertragung

J Benninghoff, München

Einfluss atypischer Neuroleptika mit hoher 5-HT_{1A} Rezeptor-Affinität auf Stammzell-Migration und de-novo Neurogenese

J Priller, Berlin

Tryptophan-Hydroxylase (TPH) und Beeinflussung der Neurogenese

S Dehning, München

Die Rolle des 5HT_{2C}-Rezeptors in der Pathophysiologie des Tourette-Syndroms

13:45-15:45 Symposium XIX

Vulnerability and resilience factors in depression and dementia: From molecular regulation to clinic

Vorsitz: E. Holsboer-Trachsler / U. Hemmeter

M Ising, München

Genetic basis of neurobiological vulnerability markers for the development of major depression

A Eckert, Basel

Oxidative stress and clinical implications in dementia

U Hemmeter, Marburg

The impact of sleep regulation and cognitive performance in elderly subjects with dementia and depression.

S Brand, Basel

Psychological vulnerability factors and neuroendocrine and sleep regulation in healthy children and adolescents

M Hatzinger, Basel

Neuroendocrine and sleep regulation as predictors of illness course and therapy in depression

13:45-15:45 Symposium XX

**Einsatz bildgebender Verfahren zur Therapieprädiktion und –
evaluation der ADHS**

Vorsitz: Thomas Frodl / Johanna Krause

J Krause, München

99mTRODAT-1-Spect als Prädiktor des Therapieansprechens von
Methylphenidat bei erwachsenen ADHS-Patienten

A Fallgatter, Würzburg

Elektrophysiologische Endophänotypen der ADHS als Ansätze zur
Therapieprädiktion

M Colla, Berlin

MR-spektroskopische und neuropsychologische Befunde in der
Therapieevaluation der ADHS

T Frodl, München

Die Psychopathologie und Neurobiologie der ADHS im Erwachsenenalter

16:00-18:00 Satellitensymposium IV

**Depression und Schlafstörung
Melatonergen Agonismus - Ein neues Therapiekonzept
Vorsitz: HJ Möller, München**

B Lemmer, Heidelberg
Bedeutung der Chronobiologie in der Psychiatrie

M Wiegand, München
Neurobiologische und klinische Zusammenhänge von Depression
und Schlafstörungen

E Fuchs, Göttingen
Präklinische Forschungsergebnisse zum melatonergen Agonismus

HJ Möller, München
Klinische Wirksamkeit eines spezifischen Melatonin-Agonisten und 5HT_{2c}-
Antagonisten in der Behandlung depressiver Störungen

G Laux, Wasserburg
Sicherheit und Verträglichkeit antidepressiver Therapien:
Bedeutung für die Lebensqualität und Compliance der Patienten

G Hajak, Regensburg
Die Rolle eines Melatonin-Agonisten und 5HT_{2c}-Antagonisten bei Depression
und gestörtem Schlaf-Wach-Rhythmus

Organisiert durch Servier Deutschland GmbH, München

18:15-19:15 Satellitensymposium V

Kognitive Aspekte der Depression und Schizophrenie
Vorsitz: I Sillaber, München

S Reppermund, München
Kognitive Störungen bei Depression und Schizophrenie

F Ohl, Uetrecht
Experimentelle Ansätze zur Untersuchung kognitiver Prozesse im Labortier

N Müller, München
Behandlungsstrategien kognitiver Symptome bei depressiven und
schizophrenen Patienten

Organisiert durch Affectis Pharmaceuticals AG, München